Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer

Trial ID #	NCT02766582
Phase	II
Drug Class	Immunotherapy: Checkpoint Inhibitors/PD-1
Drug Name	Pembrolizumab
Alternate Drug Names	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475
Drugs in Trial	Carboplatin, Paclitaxel, Pembrolizumab
Eligible Participant	Stage III–IV epithelial ovarian cancer with residual disease after cytoreductive surgery
Patients Enrolled	28
Therapy Setting	First-line
Study Design	Open-Label, Non-randomized
Endpoints	PFS, evaluated per RECIST
Efficacy	PFS (6 months): 82% PFS (9 months): 77% PFS (12 months): 59%
Clinically Significant Adverse Events	Serious AE: Grade 3-4 AE: neutropenia (67%), anemia (25%), respiratory (10%)
Conclusion	Pembrolizumab with carboplatin+paclitaxel on a weekly schedule is overall well tolerated and 12 months PFS is promising
Reference	Uyar D et al. Preliminary results from phase II trial of pembrolizumab with first line platinum based chemotherapy followed by maintenance pembrolizumab for patients with suboptimally cytoreduced advanced epithelial ovarian cancer. SGO (2020) abstract 314 https://sgo.confex.com/sgo/2020/meetingapp.cgi/Paper/15969